Maridose Introduces Innovative CRO Collective for Advancing Development of Cannabis-Based Pharmaceuticals
Tuesday, December 12, 2023
Maridose, a leading manufacturer licensed by the DEA and specializing in cannabis-based products, is excited to introduce its innovative Contract Research Organization (CRO) group. This newly formed unit is dedicated to collaborating with researchers involved in developing cannabis-based drugs for pre-clinical and clinical trials, as well as aiding in the subsequent commercialization process.
Acknowledging the growing opportunities and the essential need for advanced research in the field of cannabis-based medicine, Maridose is strategically positioned to facilitate breakthroughs in the pharmaceutical and biotech sectors. The company's unique CRO services cater to pharmaceutical and biotech firms, academic institutions, authorized cannabis companies, and other entities legally permitted to conduct research on Schedule I drugs.
Maridose's CRO services encompass a comprehensive suite of offerings designed to support every phase of drug development, ranging from initial research to final commercialization. These services include, but are not limited to:
- Pre-Clinical and Clinical Trial Support: Providing expertise in the design, execution, and monitoring of pre-clinical and clinical trials for cannabis-derived pharmaceuticals.
- Regulatory Guidance: Assisting clients in navigating the intricate regulatory landscape, providing advice on obtaining necessary licenses for research involving Schedule I substances.
- Formulation Development: Collaborating with researchers to optimize drug formulations for enhanced efficacy and safety.
- Quality Control and Assurance: Implementing stringent quality control measures to ensure compliance with industry standards and regulatory requirements.
Lisa Rich-Milan, the CEO of Maridose, expressed enthusiasm about this pivotal development, stating, "As the sole DEA licensed manufacturer offering comprehensive CRO services, the launch of our CRO group marks a significant milestone for the research community. We are dedicated to fostering advancements in cannabis-based medicine and are committed to supporting researchers and organizations striving to make breakthroughs in this rapidly evolving field."
Source: prnewswire.com
